Last reviewed · How we verify
N-methyl-pyrrolidone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
N-methyl-pyrrolidone (N-methyl-pyrrolidone) — Peter MacCallum Cancer Centre, Australia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| N-methyl-pyrrolidone TARGET | N-methyl-pyrrolidone | Peter MacCallum Cancer Centre, Australia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- N-methyl-pyrrolidone CI watch — RSS
- N-methyl-pyrrolidone CI watch — Atom
- N-methyl-pyrrolidone CI watch — JSON
- N-methyl-pyrrolidone alone — RSS
Cite this brief
Drug Landscape (2026). N-methyl-pyrrolidone — Competitive Intelligence Brief. https://druglandscape.com/ci/n-methyl-pyrrolidone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab